Abstract:A patient presented with symptoms of decompensated heart failure 2 months after percutaneous mitral valve (MV) repair. Echocardiography demonstrated impaired left ventricular function with elevated MV pressure gradients and pulmonary pressures during rapid atrial fibrillation. Heart rate control was achieved by implantation of a biventricular pacemaker with subsequent His‐bundle ablation because atrial fibrillation was refractory to medical treatment. During biventricular pacing at different rates (50–110 b.p.… Show more
“…The gradient over it, as in artificial mitral valves or after percutaneous valve repair, seems dependent on heart rate, as filling of the ventricle occurs over a shorter time interval. 6 Even though the valve itself in a Melody is a bovine jugular valve, the stent acts as a fixed valve annulus, comparable to mechanical valves. An increase in echocardiographic Doppler-derived gradients maybe interpreted as progressive stenosis.…”
The Melody valve, designed for implantation into the pulmonary outflow tract, can also be used to treat the pathology of atrioventricular (AV) valves. Increasing gradients are seen as an indication for re-dilating the valve. Our case demonstrates the heart rate dependency of the gradient across a Melody implanted in the left AV valve position in an infant. Beta blockers were used to lower both heart rate and gradient.
“…The gradient over it, as in artificial mitral valves or after percutaneous valve repair, seems dependent on heart rate, as filling of the ventricle occurs over a shorter time interval. 6 Even though the valve itself in a Melody is a bovine jugular valve, the stent acts as a fixed valve annulus, comparable to mechanical valves. An increase in echocardiographic Doppler-derived gradients maybe interpreted as progressive stenosis.…”
The Melody valve, designed for implantation into the pulmonary outflow tract, can also be used to treat the pathology of atrioventricular (AV) valves. Increasing gradients are seen as an indication for re-dilating the valve. Our case demonstrates the heart rate dependency of the gradient across a Melody implanted in the left AV valve position in an infant. Beta blockers were used to lower both heart rate and gradient.
“…The principle of MitraClip is based on Alfieri's edge‐to‐edge repair, where the anterior and the posterior leaflets are grasped and attached at the location of the regurgitation jet, thus creating a double orifice MV . Several clips can be implanted until the regurgitation is sufficiently reduced, but MV orifice area during diastole has to be monitored carefully during the procedure because elevated mitral gradients after TMVR are associated with adverse outcome . The edge‐to‐edge repair technique is a symptomatic therapy because the mechanism, either leaflet tethering or annulus dilatation, is not targeted.…”
“…[18][19][20] Several clips can be implanted until the regurgitation is sufficiently reduced, but MV orifice area during diastole has to be monitored carefully during the procedure because elevated mitral gradients after TMVR are associated with adverse outcome. 21,22 The edge-to-edge repair technique is a symptomatic therapy because the mechanism, either leaflet tethering or annulus dilatation, is not targeted.…”
Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi‐parametric approach. Severe secondary MR occurs in up to one‐fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge‐to‐edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics. Further new transcatheter strategies addressing MR are evolving. The Carillion, Cardioband, and Mitralign devices were designed to reduce the annulus dilatation, which is a frequent and important determinant of secondary MR. Several transcatheter mitral valve replacement systems (Tendyne, CardiAQ‐Edwards, Neovasc, Tiara, Intrepid, Caisson, HighLife, MValve System, and NCSI NaviGate Mitral) are emerging because valve replacement might be more durable compared with valve repair. In small studies, these interventional therapies demonstrated feasibility and efficiency to reduce MR and to improve heart failure symptoms. However, neither transcatheter nor surgical mitral valve repair or replacement has been proven to impact on the prognosis of heart failure patients with severe MR, which remains high with a mortality rate of 14–20% at 1 year. To date, the primary indication for treatment of secondary severe MR is the amelioration of symptoms, reinforcing the value of a Heart Team discussion. Randomized studies to investigate the treatment effect and long‐term outcome for any transcatheter or surgical mitral valve intervention compared with optimized medical treatment are urgently needed and underway.
“…MitraClip patients with post-procedural moderate MS (mean MVG 5 mmHg), where the overall rate of moderate MS among patients treated with MitraClip was found to be 25% [4,5]. In FMR patients in particular, MS severity after MitraClip may be further exacerbated by diastolic restriction of the anterior mitral leaflet (AML) caused by severe dilatation of the left ventricle (LV) and papillary muscle (PM) displacement [6].…”
Section: Deteriorated Long-term Outcomes Have Been Recently Demonstramentioning
confidence: 99%
“…In many cases, multiple MitraClip devices are used to treat MR , though placement of additional devices can further reduce mitral valve area (MVA) and increase of mean mitral valve gradient (MVG), leading to mitral stenosis (MS) . Deteriorated long‐term outcomes have been recently demonstrated in MitraClip patients with post‐procedural moderate MS (mean MVG ≥ 5 mmHg), where the overall rate of moderate MS among patients treated with MitraClip was found to be 25% . In FMR patients in particular, MS severity after MitraClip may be further exacerbated by diastolic restriction of the anterior mitral leaflet (AML) caused by severe dilatation of the left ventricle (LV) and papillary muscle (PM) displacement .…”
Our results show that diastolic AML tethering may predispose to MS after clip placement, however, MS was not observed when baseline MVA was above 4.0 cm . Severity of AML tethering may be an important criterion in selecting patients for edge-to-edge repair.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.